دورية أكاديمية
أعرض في EDS

Genetics of ABCB1 in Cancer.

التفاصيل البيبلوغرافية
العنوان: Genetics of ABCB1 in Cancer.
المؤلفون: Skinner KT; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA., Palkar AM; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA., Hong AL; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
المصدر: Cancers [Cancers (Basel)] 2023 Aug 24; Vol. 15 (17). Date of Electronic Publication: 2023 Aug 24.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: ABCB1 , also known as MDR1 , is a gene that encodes P-glycoprotein (P-gp), a membrane-associated ATP-dependent transporter. P-gp is widely expressed in many healthy tissues-in the gastrointestinal tract, liver, kidney, and at the blood-brain barrier. P-gp works to pump xenobiotics such as toxins and drugs out of cells. P-gp is also commonly upregulated across multiple cancer types such as ovarian, breast, and lung. Overexpression of ABCB1 has been linked to the development of chemotherapy resistance across these cancers. In vitro work across a wide range of drug-sensitive and -resistant cancer cell lines has shown that upon treatment with chemotherapeutic agents such as doxorubicin, cisplatin, and paclitaxel, ABCB1 is upregulated. This upregulation is caused in part by a variety of genetic and epigenetic mechanisms. This includes single-nucleotide variants that lead to enhanced P-gp ATPase activity without increasing ABCB1 RNA and protein levels. In this review, we summarize current knowledge of genetic and epigenetic mechanisms leading to ABCB1 upregulation and P-gp-enhanced ATPase activity in the setting of chemotherapy resistance across a variety of cancers.
References: FEBS Lett. 2021 Mar;595(6):707-716. (PMID: 33275773)
Drug Discov Today. 2023 May;28(5):103537. (PMID: 36801375)
J Biol Chem. 1999 Aug 27;274(35):24759-65. (PMID: 10455147)
FASEB J. 2008 Dec;22(12):4201-8. (PMID: 18757502)
Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8. (PMID: 2563168)
Drug Metab Dispos. 2018 May;46(5):561-566. (PMID: 29636376)
Cancer Res. 2016 Oct 1;76(19):5810-5821. (PMID: 27503929)
Mol Pharm. 2021 May 3;18(5):1895-1904. (PMID: 33886332)
BMC Genomics. 2013 Dec 17;14:898. (PMID: 24344919)
J Biol Chem. 1993 Oct 15;268(29):21493-6. (PMID: 8104940)
Genome Res. 2001 Jul;11(7):1156-66. (PMID: 11435397)
Br J Cancer. 1995 Aug;72(2):307-11. (PMID: 7640210)
J Pharm Sci. 2008 Jun;97(6):2045-8. (PMID: 17828752)
Eur J Pharm Sci. 2006 Apr;27(5):392-400. (PMID: 16352426)
Mol Pharmacol. 2019 Nov;96(5):629-640. (PMID: 31515284)
Leuk Lymphoma. 2015 Jan;56(1):26-33. (PMID: 24678978)
J Cell Biochem. 2019 Oct;120(10):18406-18414. (PMID: 31209929)
N Engl J Med. 2016 Sep 22;375(12):1109-12. (PMID: 27653561)
Proc Natl Acad Sci U S A. 1987 Jan;84(1):265-9. (PMID: 2432605)
Environ Res. 2015 Nov;143(Pt A):98-106. (PMID: 26457621)
Biochem Biophys Res Commun. 2002 Dec 6;299(3):410-7. (PMID: 12445816)
Genes Chromosomes Cancer. 2006 Apr;45(4):365-74. (PMID: 16382445)
Exp Cell Res. 2006 Dec 10;312(20):4070-8. (PMID: 17027968)
Cancer Chemother Pharmacol. 1995;35(5):432-6. (PMID: 7850926)
J Clin Invest. 2005 Nov;115(11):3285-90. (PMID: 16239972)
Biochim Biophys Acta. 2002 Sep 20;1565(1):6-16. (PMID: 12225847)
Mol Cancer Ther. 2007 Jul;6(7):2092-102. (PMID: 17620438)
Pak J Med Sci. 2014 Jul;30(4):886-90. (PMID: 25097538)
Biochem Biophys Res Commun. 1989 Aug 15;162(3):1402-8. (PMID: 2569869)
DNA Cell Biol. 2019 May;38(5):485-490. (PMID: 30977678)
Cancer Sci. 2013 Oct;104(10):1303-8. (PMID: 23822562)
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. (PMID: 10716719)
Nature. 2015 May 28;521(7553):489-94. (PMID: 26017449)
J Biol Chem. 1990 Mar 5;265(7):3975-80. (PMID: 1968065)
Coll Antropol. 2009 Dec;33(4):1145-50. (PMID: 20102060)
Biochem Biophys Res Commun. 2020 Jun 4;526(3):586-591. (PMID: 32247608)
Int Orthop. 2001;24(6):307-10. (PMID: 11294418)
Clin Pharmacol Ther. 2001 Aug;70(2):189-99. (PMID: 11503014)
J Biol Chem. 2020 Apr 10;295(15):5002-5011. (PMID: 32111736)
J Am Soc Nephrol. 2002 Jul;13(7):1847-54. (PMID: 12089380)
Front Pharmacol. 2012 Jul 09;3:126. (PMID: 22787449)
Trends Biochem Sci. 1992 Jan;17(1):18-21. (PMID: 1374941)
J Biol Chem. 1992 Dec 5;267(34):24248-52. (PMID: 1360010)
BMC Cancer. 2012 Jul 23;12:303. (PMID: 22823957)
J Histochem Cytochem. 2006 Oct;54(10):1159-67. (PMID: 16801529)
Biochem J. 2005 Jul 15;389(Pt 2):517-26. (PMID: 15799713)
J Hepatol. 1995 Oct;23(4):440-8. (PMID: 8655962)
Contracept Reprod Med. 2018 Nov 15;3:26. (PMID: 30460040)
Int J Cancer. 2008 Mar 1;122(5):1058-67. (PMID: 17955490)
Pharmacogenetics. 2001 Jun;11(4):293-8. (PMID: 11434506)
BMC Med. 2021 Dec 8;19(1):311. (PMID: 34876109)
PLoS Med. 2020 Nov 23;17(11):e1003372. (PMID: 33226983)
Oncol Rep. 2012 May;27(5):1535-40. (PMID: 22307172)
Int J Mol Sci. 2022 Aug 09;23(16):. (PMID: 36012140)
PLoS One. 2021 Apr 26;16(4):e0250371. (PMID: 33901197)
J Clin Pharm Ther. 2019 Apr;44(2):188-196. (PMID: 30637776)
Drug Metab Dispos. 2021 Oct;49(10):919-928. (PMID: 34426410)
Science. 1992 Jan 24;255(5043):459-62. (PMID: 1346476)
Sci Rep. 2015 Nov 18;5:16724. (PMID: 26577702)
Cancer Sci. 2006 Nov;97(11):1198-204. (PMID: 16925584)
J Clin Invest. 1998 Jan 15;101(2):289-94. (PMID: 9435299)
Br J Cancer. 2018 Jun 25;119:182-192. (PMID: 29937544)
Int Rev Cytol. 1999;190:175-250. (PMID: 10331240)
Jpn J Cancer Res. 2002 Mar;93(3):231-5. (PMID: 11927002)
Clin Pharmacol Ther. 2002 Apr;71(4):297-303. (PMID: 11956513)
J Pharmacol Exp Ther. 2004 Sep;310(3):1199-207. (PMID: 15100388)
Eur J Biochem. 1997 Nov 15;250(1):115-21. (PMID: 9431998)
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8. (PMID: 2444983)
Br J Cancer. 1996 Dec;74(12):1929-34. (PMID: 8980392)
J Biol Chem. 1995 Jul 7;270(27):16167-75. (PMID: 7608182)
J Biol Chem. 1990 Jan 5;265(1):506-14. (PMID: 1967175)
Biochemistry. 2005 Aug 16;44(32):10893-904. (PMID: 16086592)
Jpn J Cancer Res. 1989 Oct;80(10):1006-13. (PMID: 2575608)
Curr Alzheimer Res. 2017;14(6):656-667. (PMID: 27915995)
Nat Commun. 2019 Mar 20;10(1):1295. (PMID: 30894541)
Am J Physiol Cell Physiol. 2000 Jun;278(6):C1256-65. (PMID: 10837354)
Nature. 1985 Aug 29-Sep 4;316(6031):817-9. (PMID: 2863759)
Sci Rep. 2020 Apr 10;10(1):6188. (PMID: 32277145)
J Cardiovasc Pharmacol. 2006 Jan;47(1):55-9. (PMID: 16424786)
Cancer Chemother Pharmacol. 1998;41(6):517-21. (PMID: 9554598)
Biochem Pharmacol. 2006 Apr 14;71(8):1162-74. (PMID: 16499877)
Arch Neurol. 2010 Jun;67(6):739-45. (PMID: 20558393)
Pharmacogenet Genomics. 2005 Oct;15(10):693-704. (PMID: 16141795)
Clin Pharmacokinet. 2015 Jul;54(7):709-35. (PMID: 25860377)
J Biol Chem. 1993 Nov 15;268(32):24197-202. (PMID: 7901214)
Asian Pac J Cancer Prev. 2015;16(18):8467-71. (PMID: 26745103)
Bioinformation. 2018 Dec 29;14(9):587-593. (PMID: 31223218)
Endocrinology. 2006 Nov;147(11):5147-52. (PMID: 16873536)
Fluids Barriers CNS. 2021 Mar 6;18(1):10. (PMID: 33676539)
Clin Cancer Res. 2004 Apr 15;10(8):2776-83. (PMID: 15102684)
Biochim Biophys Acta. 1976 Nov 11;455(1):152-62. (PMID: 990323)
FEBS Lett. 1996 Dec 9;399(1-2):29-32. (PMID: 8980113)
J Mol Med (Berl). 2021 Nov;99(11):1527-1538. (PMID: 34370042)
Anticancer Res. 2013 Dec;33(12):5317-23. (PMID: 24324065)
Antimicrob Agents Chemother. 2004 Mar;48(3):809-14. (PMID: 14982769)
Front Oncol. 2020 Oct 26;10:576559. (PMID: 33194688)
Oncotarget. 2016 Jan 19;7(3):3506-19. (PMID: 26654944)
Pharmaceutics. 2011 Oct 27;3(4):782-92. (PMID: 24309308)
Clin Cancer Res. 2006 Oct 1;12(19):5786-93. (PMID: 17020985)
Biochem Pharmacol. 2016 Oct 15;118:96-108. (PMID: 27531061)
J Biol Chem. 2017 Dec 15;292(50):20412-20424. (PMID: 29018094)
J Bioenerg Biomembr. 2001 Dec;33(6):475-9. (PMID: 11804189)
Cancer Res. 1996 Sep 15;56(18):4171-9. (PMID: 8797588)
Carcinogenesis. 2011 May;32(5):667-75. (PMID: 21296766)
Int J Exp Pathol. 2016 Dec;97(6):412-421. (PMID: 27995666)
Metabolism. 2022 Mar;128:155118. (PMID: 34990712)
Epigenetics. 2008 Sep;3(5):270-80. (PMID: 19001875)
Eur J Cancer. 1994;30A(7):1002-7. (PMID: 7946563)
Anal Biochem. 2010 Apr 15;399(2):246-50. (PMID: 20018165)
Anticancer Drugs. 2000 Apr;11(4):303-9. (PMID: 10898547)
Front Oncol. 2014 Mar 03;4:41. (PMID: 24624364)
PLoS One. 2014 Oct 29;9(10):e111135. (PMID: 25353162)
PLoS One. 2017 Jan 3;12(1):e0166061. (PMID: 28045902)
Biochemistry. 1998 Mar 17;37(11):3594-601. (PMID: 9530286)
J Hypertens. 2019 Nov;37(11):2225-2231. (PMID: 31157746)
Science. 1983 Sep 23;221(4617):1285-8. (PMID: 6137059)
Placenta. 2006 Jun-Jul;27(6-7):602-9. (PMID: 16143395)
Methods Enzymol. 1998;292:492-504. (PMID: 9711577)
Nucl Med Biol. 2013 Oct;40(7):873-8. (PMID: 23845421)
معلومات مُعتمدة: MRSG-18-202-01-TBG American Cancer Society; 22IC37 Rally Foundation
فهرسة مساهمة: Keywords: ABCB1; chemotherapy; epigenetics; genetics; multidrug resistance
تواريخ الأحداث: Date Created: 20230909 Latest Revision: 20230911
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10487083
DOI: 10.3390/cancers15174236
PMID: 37686513
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15174236